- 更多网络例句与抑制物相关的网络例句 [注：此内容来源于网络，仅供参考]
-
In laparoscopies, peritoneal biopsies were opened after carbon dioxide insufflation and were closed just before exsufflation.
方法在腹腔镜与开腹手术前、后、立即，分别测量腹膜组织中组织型纤溶酶原激活物、纤溶酶原激活物抑制物(PAI-1)的浓度及t-PA的活性。
-
Plasma urokinaseantigen,tissue plasminogen activator antigen, plasminogen activatoractivity, plasminogen activator inhibiter activity, plasmin activity and fibrinogen antigen Were measured before and after thrombolytic treatment with intravenous UK in 44 patients suffering from their first attack of acute myocardial infarction.
观察44例首次急性心肌梗塞患者的尿激酶静脉溶栓治疗前后血浆UK抗原、组织纤溶酶原激活物抗原、纤溶酶原激活物活性、纤溶酶原激活物抑制物活性、纤溶酶活性和纤维蛋白原抗原的变化。
-
At pre-operation, post-operation 6 h, 3 d and 7 d detect the leave of plasm prethrombotic state molecular marker tissue factor, tissue factor pass inhibitory, thrombus precursor protein, plasminogen activator inhibitory-1(PAI-1), P-Selectin, Thrombin-Antithrombin complexes, D-dimer with ELISA, transmission immunity nephelometer. Results Malignant tumor patients, the levels of plasma TF, TpP, D-D in 6 h and 3 d of post-operation rose to peak value.
分别于术前、术后6 h3、d和7 d用ELISA、透射免疫比浊法检测其血浆血栓前状态分子标志物D-二聚体(D-dimer， D-D)、血栓前体蛋白(thrombus precursor protein， TpP)、凝血酶抗凝血酶复合物(thrombin-antithrombin complexes， TAT)、组织因子(tissue factor， TF)、P选择素(P-Selectin， P-S)、组织因子途径抑制物(tissue factor pass inhibitory， TFPI)、纤溶酶原激活物抑制物1(plasminogen activator inhibitory-1， PAI-1)的水平。
-
In order to study the ability to the thrombus formation,41 patients with essential hypertension and 34 patients with normotension were investigated.The plasma level of fibrinogen and tissue-type plasminogen activator antigen and plasminogen activator inhibitor 1(PAI-1)antigen were determined.
为了解高血压病人的血栓形成倾向，我们随机选取了41例高血压病人及34例正常血压者，分别观察了他们的纤维蛋白原及血浆组织型纤溶酶原激活物抗原及纤溶酶原激活物抑制物-1(PAI-1)的含量。
-
objective to invetigate the variations of plasminogen activator inhibitor-1(pai-1) and tissue-type plsminogen activator in patients with diabetic nephropathy.
目的 探讨2型糖尿病（t2dm）患者血浆纤溶酶原激活物抑制物（pai-1）和组织型纤溶酶原激活物活性水平的变化及其与糖尿病肾病的关系。
-
The study showed the recombinant wt/mCREG protein depressed the VSMC proliferation depending on dose and the optimal concentration was 400nM;2biologic function of CREG protein and the membrance receptor mechanism:①effect on VSMC migration: the wound healing experiment showed the OB2 cells migration was slower significantly after added wt/mCREG(400Nm) in supernatant. The HITASY cells migration were very slowly and no remarkable change. The gelatinase digestion and Western blot analysis showed the matrix metalloproteinase was decreased and TIMPs was increased;②effect on differentiation: after added wt/mCREG(400nM), the expression of myocardin, SMα-actin, MHC and caldesmin were increased and that of LM-1 and FN were decreased in OB2 cells. These effects were more significant when adding wtCREG.;③effect on VSMC proliferation: Cell cycle assay and BrDU stain showed: after added the wtCREG and mCREG protein, the ratio of cell in G0/G1 phase increased to 0.5773 and 0.5572 from 0.5308 respectively in OB2 group, which increased to 0.7369 and 0.7034 respectively from 0.6297 in HITASY group;3Role of M6P/IGF2R in CREG biologic function:①ELISA and co-immunoprecipitation showed the wt/mCREG binding to M6P/IGF2R directly.②antibody blocking test: when the anti-IGF2R was added to medium at the same time with wt/mCREG at different concentration(2μg/mL、4μg/mL、8μg/mL),the effects of CREG protein which depressing proliferation, migration, secretion and promoting differentiation were blocked, which had the positive correlation to the concentration of added anti body. The studies showed two combinant CREG promoted VSMC switch to differentiation phaenotype, at the same time, depress VSMC proliferation, migration and secreting extracellular matrix.
上述实验结果证实：两种重组CREG蛋白对VSMC增殖均有剂量依赖性的抑制作用，并且相同浓度的糖基化的CREG蛋白对细胞增殖的抑制效应更为显著，最佳效应浓度为400nM；2两种重组CREG蛋白添加后对HITASY和OB2细胞生物学行为的影响：①CREG蛋白对VSMC迁移的影响：刮伤实验发现，加入最佳效应浓度的wtCREG和mCREG蛋白24h后，OB2组迁移能力下降，HITASY组无明显变化；细胞外基质金属蛋白酶-2，9(Matrix metallo-proteinase 2，9，MMP2 ，9)明胶酶电泳检测和Western blot检测结果证实，两种CREG蛋白均可以使OB2细胞合成细胞外基质MMP2，9减少，而组织金属蛋白酶抑制物(Tissue Inhibitors of Metalloproteinases，TIMPs)增加；②CREG蛋白对VSMC分化的影响：加入400nM的wtCREG和mCREG蛋白12h后，OB2细胞myocardin、SMα-actin、MHC、caldesmin表达增加，LM-1、FN表达减少；③流式细胞仪分析细胞周期和BrDU染色分析证实，加入400nM的wtCREG和mCREG蛋白后，OB2组G0/G1期细胞由0.5308分别增加至0.5773和0.5572，HITASY组G0/G1期细胞由0.6297分别增加至0.7369和0.7034；3M6P/IGF2R在重组CREG蛋白的生物学功能中的调控作用：①免疫共沉淀和免疫荧光双染色分析结果显示，CREG蛋白与M6P/IGF2R存在直接结合；②应用抗体阻断实验：将不同浓度的anti- M6P/IGF2R(2、4、8μg /mL)与两种CREG蛋白同时加入培养液中，CREG蛋白抑制VSMC增值、迁移和合成细胞外基质、促进分化的效应减弱，而且与加入anti- M6P/IGF2R浓度正相关。
-
Objective To study the relationship of endangium proliferation and the expression of metalloproteinases and tissue inhibitors of metalloproteinases after angioplasty of iliac artery in rabbits to investigate the probable mechanism of composite Danshen pill in prevention and treatment of restenosisMethods 30 white male rabbits of Japan （the average body weight was 25～30 kg）were randomly divided into 3 groups:normal control group,model group (intima destroyed by balloon and given hypercholesterol diet),CDP group (intima destroyed by balloon and given hypercholesterol diet plus drug CDP 150 mg/d),10 ones each groupResults The results of iliac artery angiogram and the analysis of pathology:there were lumens stenosis,thinner intima,smaller intima area,in CDP group compared with those in model group,and ratio of intima and tunica media thickness and area among each group (P＜001)Immunohistochemistry analysis:the MMP2,MMP9,TIMP1,TIMP2 in model group significantly increased than those in control group (P＜001)The CDP group had lower MMP2 and MMP9 expression,higher TIMP1 and TIMP2 expression,and increased MMP2/TIMP1,MMP9/TIMP2 than model group (P＜001)The thickening of vascular neointima and stenosis degree of vascular lumen were relevant to MMP2 and MMP9 (r=0896,P＜001)Conclusions MMP and TIMP play the very important role in the restenosis process of arteryCDP could inhibit the thickness of vascular neointima after balloon injury,the probable mechanism of which may be inhibiting collagen formation,smooth muscle immigration and decreasing hyperplasia of intima by interfering expression of MMPs and TIMPs
目的 研究兔髂动脉成形术后血管内膜增生和基质金属蛋白酶及其抑制物表达之间的关系，探讨复方丹参滴丸预防再狭窄的可能机制。方法健康成年二级雄性日本大耳白兔30只，平均体重25～30 kg。随机分为3组：正常对照组10只，模型组10只（球囊内膜剥脱加高胆固醇饮食），治疗组10只（球囊内膜剥脱加高胆固醇饮食以及复方丹参滴丸150 mg/d）。结果兔髂动脉造影、血管病理图像分析检测结果：①复方丹参滴丸组较模型组血管造影示管腔直径狭窄、内膜厚度减少、内膜面积减少、内膜厚度和中膜厚度比、面积比，各组之间有显著性差异(P＜001)。②免疫组化分析：模型组MMP2、MMP9、TIMP1、TIMP2表达均高于对照组（P＜001）；复方丹参滴丸组MMP2、MMP9的表达低于模型组，而TIMP1、TIMP2的表达高于模型组；TIMP1/MMP2、TIMP2/MMP9明显增加，差异有显著性（P＜001）。③内膜的增生以及管腔的狭窄程度与MMP2、MMP9有很好的相关性(r=0896，P＜001)。结论 MMP和TIMP在再狭窄形成中起重要作用；复方丹参滴丸能够明显抑制血管损伤后的内膜增生，可能的机制是通过影响金属蛋白酶MMP2、MMP9及其抑制物TIMP1、TIMP2的表达从而抑制胶原的生成、平滑肌的迁移、增生，而减少内膜的增生。
-
Methods The activity of plasma t-PA and PAI were detected by enzyme linked immunosorbent assay respectively in 40 cases with hypertensive disorder complicating pregnancy, 20 nonfertile women and 20 pregnant women.
采用发色底物法和酶联免疫吸附法测定40例妊娠期高血压疾病患者、20例正常非孕妇女及20例正常晚孕妇女血浆组织纤溶酶原激活物及其抑制物活性，并进行比较。
-
Inhibition of SAHH has been known to result in accumulation of intracellular levels of AdoHcy, which is a potent inhibitor of all S-adenosyl-L-methionine-dependent transmethylation reactions.
抑制SAHH将导致细胞内甲基化抑制物AdoHcy的堆积，从而时转甲基反应产生反馈性抑制作用。而甲基化对于维持细胞的活性是必需的。
-
Inhibition of SAHH has been known to result in accumulation of intracellular levels of AdoHcy, which is a potent inhibitor of all S -adenosyl- L -methionine-dependent transmethylation reactions.
抑制SAHH将导致细胞内甲基化抑制物AdoHcy的堆积，从而对转甲基反应产生反馈性抑制作用。而甲基化对于维持细胞的活性是必需的。
- 更多网络解释与抑制物相关的网络解释 [注：此内容来源于网络，仅供参考]
-
metabolic antagonism：代謝拮抗 代谢抑制物(抗代谢物)
message 信息 信息 | metabolic antagonism 代謝拮抗 代谢抑制物(抗代谢物) | metabolic degradation 代謝性降解 代谢性降解
-
metabolic antagonist：代谢抑制物
反馈调节 feedback regulation | 代谢抑制物 metabolic antagonist | 抗菌谱 antimicrobial spectrum
-
thrombin-activatable fibrinolysis inhibitor TAFI：凝血酶激活的纤溶抑制物
thalamus 丘脑 | thrombin-activatable fibrinolysis inhibitor TAFI 凝血酶激活的纤溶抑制物 | thrombomodulinTM 血栓调节蛋白
-
thrombin-activatable fibrinolysis inhibitor TAFI：凝血酶活化纤溶抑制物 第三章
thrombin 凝血酶 第三章 | thrombin-activatable fibrinolysis inhibitor, TAFI 凝血酶活化纤溶抑制物 第三章 | thrombocyte adhesion 血小板粘附 第三章
-
(TAFI)ELISA Kit Rat Thrombin activatable fibrinolysis inhibitor,TAFI ELISA Kit：大鼠纤溶抑制因子/凝血酶激活的纤溶抑制物
FA01861B 大鼠抗平滑肌抗体(ASMA)ELIS... | FA01863B 大鼠纤溶抑制因子/凝血酶激活的纤溶抑制物(TAFI)ELISA Kit Rat Thrombin activatable fibrinolysis inhibitor,TAFI ELISA Kit | FA02100B 大鼠皮质酮/肾上腺酮(CO...
-
inhibitor：抑制物
最后要说明许多的食物成份会相互影响吸收:增强(enhancer)和抑制物(inhibitor). 增加物指的是同时食用可以增加铁质的吸收,例如维生素C;而若是和抑制物同时食用会与铁质互相竞争吸收,例如钙质和许多植物所含植酸(phytate)会与铁质结合,
-
LI luteinization inhibitor：黄体化抑制物
LHRH luteinizing hormone releasing hormone 黄体生成素释放激素 | LI luteinization inhibitor 黄体化抑制物 | LM light microscopy 光学显微镜检查
-
PAI-1 plasm inogen activator inhibitor：1 纤溶酶原激活剂抑制物
P450scc P 450 side chain cleavage 细胞色素P450侧链裂解酶 | PAI-1 plasm inogen activator inhibitor-1 纤溶酶原激活剂抑制物 | PCOS polycystic ovary syndrome 多囊卵巢综合征
-
Mullerian inhibitory substance：穆勒氏抑制物
Mullerian duct 副中肾管,穆勒氏管 | Mullerian inhibitory substance 穆勒氏抑制物 | multi- [词头] 多
-
plasmin inhibitor：纤溶酶抑制物
plasminogen activator inhibitor 纤溶酶原激活物抑制因子 | plasmin inhibitor 纤溶酶抑制物 | fibtrinolysis 纤溶